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Cardiac preconditioning represents the most potent and consistently reproducible method of
rescuing heart tissue from undergoing irreversible ischaemic damage. Major milestones regard-
ing the elucidation of this phenomenon have been passed in the last two decades. The signalling
and ampli®cation cascades from the preconditioning stimulus, be it ischaemic or pharmaco-
logical, to the putative end-effectors, including the mechanisms involved in cellular protection,
are discussed in this review. Volatile anaesthetics and opioids effectively elicit pharmacological
preconditioning. Anaesthetic-induced preconditioning and ischaemic preconditioning share
many fundamental steps, including activation of G-protein-coupled receptors, multiple protein
kinases and ATP-sensitive potassium channels (KATP channels). Volatile anaesthetics prime the
activation of the sarcolemmal and mitochondrial KATP channels, the putative end-effectors of
preconditioning, by stimulation of adenosine receptors and subsequent activation of protein
kinase C (PKC) and by increased formation of nitric oxide and free oxygen radicals. In the case
of des¯urane, stimulation of a- and b-adrenergic receptors may also be of importance.
Similarly, opioids activate d- and k-opioid receptors, and this also leads to PKC activation.
Activated PKC acts as an ampli®er of the preconditioning stimulus and stabilizes, by phos-
phorylation, the open state of the mitochondrial KATP channel (the main end-effector in anaes-
thetic preconditioning) and the sarcolemmal KATP channel. The opening of KATP channels
ultimately elicits cytoprotection by decreasing cytosolic and mitochondrial Ca2+ overload.
Br J Anaesth 2003; 91: 551±65
Keywords: anaesthesia, perioperative; heart, cardiac preconditioning, cardioprotection
The heart possesses a remarkable ability to adapt to stress by
changing its phenotype in a manner that makes it more
resistant to further damage. Verdouw and colleagues111 and
Reimer and colleagues89 reported favourable ATP handling
in response to brief episodes of ischaemia. In 1986, Murry
and colleagues69 described, for the ®rst time, the phenom-
enon of ischaemic preconditioning in canine myocardium.
Subjecting hearts to four brief ischaemic episodes (ligation
of the circum¯ex coronary artery) interspersed with 5-min
periods of reperfusion before a prolonged 40-min ischaemic
insult reduced myocardial infarct size from 30% to only 7%
of the area at risk. Since then, this potent endogenous
protective mechanism has been con®rmed in almost all
species, including the mouse, rat, guinea-pig, rabbit, dog,
pig and, at least indirectly, the human (reviewed by
Przyklenk and Kloner).87 Moreover, ischaemic precondi-
tioning was consistently observed in single cells,60 in
superfused myocardial samples,112 in the whole heart and in
all types of in vivo experiments. A few years later, in 1993,
Marber and colleagues61 and Kuzuya and colleagues49
described another remarkable phenomenon, called late
preconditioning, which re¯ects a second delayed window
of protection 12±72 h after initiation of preconditioning.
Under most experimental conditions, preconditioning not
only reduces infarct size but also alleviates post-ischaemic
cardiac dysfunction and arrhythmias. The possibility of an
effective clinical use for this innate cardioprotective mech-
anism has generated enormous interest (more than 3000
articles published). It has elucidated the underlying signal-
ling pathways, with the ®nal aim of mimicking the
preconditioned state and its bene®ts by means of pharma-
cological agents. Pharmacological preconditioning, in place
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of ischaemia, may represent a safer way of eliciting
protection, particularly in the diseased myocardium. Two
anaesthesia research groups (Cason and colleagues9 and
Kersten and colleagues42) independently described the
preconditioning-mimicking effects of iso¯urane for the
®rst time in 1997. However, infarct-limiting properties of
halothane and iso¯urane were reported as early as 1983 and
1989 respectively by Davis and colleagues.18 19 Subsequent
extensive experimental work aimed at elucidating the
complex signalling cascade involved in anaesthetic-induced
preconditioning. Today, we know that most anaesthetics
elicit, enhance or inhibit preconditioning.119 Unlike most
other preconditioning-inducing agents, which must be
administered directly into the coronary arteries to be
effective, anaesthetics can be administered non-selectively
with relatively low toxicity. Anaesthetic-mediated or
-facilitated cardiac preconditioning around the stressful
time of surgery would be particularly bene®cial in high-risk
cardiac patients.
Mechanisms of cardiac preconditioning
De®nition and time course of preconditioned states
The classic or early preconditioned state of cardiac tissue is
an immediate consequence of multiple brief episodes of
sublethal cardiac ischaemia, and is de®ned as a state of
marked protection against subsequent prolonged ischaemia.
While multiple, brief antecedent ischaemic episodes may
have additive effects,91 too many repetitive stimuli abolish
the protection.37 Of note, preconditioning per se does not
prevent myocardial cell death, but signi®cantly delays its
occurrence during the ®rst 2±3 h of sustained ischaemia
(temporal limitation of protection). Although the gold
standard end-point for assessing the preconditioned state
and its protection is the reduction in infarct size,
preconditioning also improves post-ischaemic functional
recovery and decreases arrhythmogenicity in many experi-
mental approaches. Improved preservation of ATP reserves
and attenuated ST-segment alterations in the ECG, though
considered to be surrogate markers of effective cardiac
protection, are highly species-dependent and therefore may
not serve as valid markers for preconditioning.21 46 The
protection elicited by preconditioning is typically present
immediately after the stimulus, but vanishes after 2±3 h
(classic or early preconditioning).87 Additional, though less
pronounced, protection occurs 12±24 h after the initial
preconditioning stimulus and lasts for up to 72 h (second
window of protection or late/delayed preconditioning).6
Consistent with this delayed type of protection, late
preconditioning is dependent on de novo synthesis of
cardioprotective proteins. In contrast to most classic or early
preconditioning models, late preconditioning consistently
protects against stunning.100 Lastly, and most importantly, a
multitude of additional stressful stimuli (apart from
ischaemia), including oxidative (hyperoxia), mechanical
(stretch),75 electrical (rapid pacing), thermal and chemical
(hormonal, ionic (calcium)66 and pharmacological) stres-
sors, can induce the same archetypal early and late
protective response in cardiac tissue.
Signalling cascades and ampli®cation of the
preconditioning stimulus
Receptors
The concept that brief renal, mesenteric or skeletal muscle
ischaemia of remote origin can effectively precondition the
heart is consistent with humoral induction of the precondi-
tioned state (`remote preconditioning') (reference 116 and
references therein). Also consistent with this notion is the
fact that regional cardiac ischaemia can initiate global
protection and render remote myocardium resistant to
infarction (`preconditioning at a distance').86 Ischaemic
preconditioning is mediated via several sarcolemmal
receptors, which are mostly linked to inhibitory G-protein
(Gi),72 namely adenosine (A-1, A-3), purinoceptors (P2Y),
endothelin (ET1), acetylcholine (M2), a1- and b-adrenergic,
angiotensin II (AT1), bradykinin (B2) and opioid (d1, k)
receptors, which couple to a highly complex network of
kinases (for review see reference 3). The involvement of
many receptors or triggers in mediating preconditioning
re¯ects the biological redundancy in this life-saving signal
transduction pathway. The importance of the individual
receptors depends heavily on the species and the precondi-
tioning stimulus itself.103 The main signalling steps and
components of early and delayed preconditioning are
summarized schematically in Figure 1.
Ampli®cation of the preconditioning signal
G-proteins link the initial stimulus from the individual
receptors to phospholipases C and D but have several
additional functions, such as inhibition of Ca2+ in¯ux during
ischaemia, regulation of cellular metabolism and activation
of KATP channels, the putative main end-effectors of
preconditioning. Activation of phospholipases C and D
leads to formation of inositol triphosphate (IP3) for the
release of Ca2+ from the sarcoplasmic reticulum via the IP3
receptor, and production of diacylglycerol, which, in turn,
activates different isoforms of protein kinase C (PKC). PKC
is activated by a large number of phosphorylating enzymes,
including G-proteins, phospholipids, diacylglycerol, in-
creased intracellular Ca2+, and nitric oxide (NO), which is
derived from intracellular constitutively active NO synthase
(NOS) or from extracellular sources. PKC can be activated
by reactive oxygen species (ROS) arising from mitochon-
dria either during the short ischaemic or the subsequent
repetitive reperfusion episodes. Activation of this key
enzyme leads to isoform-speci®c and cytoskeleton-medi-
ated translocation of cytosolic PKC, ultimately inducing
phosphorylation and thus activation of the sarcolemmal and
mitochondrial KATP channels, the putative end-effectors of
early but also delayed preconditioning56 (Fig. 1). Isoform-
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speci®c translocation of PKC allows the enzyme to take up
the correct position to phosphorylate the targets. After only
10 min of ischaemic preconditioning, PKC activity in the
cytosol decreases, whereas PKC in the particulate fraction
(i.e. nuclei, mitochondria and membranes) increases.98
PKC-d translocation seems to be responsible for activating
mitochondrial KATP channels and PKC-e translocation for
the establishment of late preconditioning by phosphorylat-
ing nuclear targets.39 However, activation of speci®c PKC
isoforms is species-dependent and further depends on the
pathological stimuli.103 The observation that PKC inhibition
may not necessarily completely block the preconditioning
stimulus110 supports the concept that additional intracellular
kinases downstream, upstream or in parallel to PKC
signalling contribute to the ampli®cation and establishment
of the preconditioned state (the `molecular chain reaction of
kinases'). As PKC inhibitors failed to affect preconditioning
in dogs and pigs,88 110 alternative kinases may be involved
in preconditioning. Inhibition of protein tyrosine kinases
clearly abrogates the reduction in infarct size in rabbits, and
may thus be as important as or more important than PKC
under certain circumstances.83 Additionally, some studies
propose activation of ERK (extracellular signal-regulated
kinase), JNK (c-jun N-terminal kinase) and p38MAPK
(mitogen-activated protein kinase) as mediators of pre-
conditioning, while others suggest the inhibition of these
kinases as favourable (for review see reference 3). These
contradictory results may be due to the existence of various
isoenzymes of speci®c kinases that possess differential
biological functions and to the restricted selectivity of the
various pharmacological blockers used in the reported
experiments. Finally, the involvement of multiple phospha-
tases, which are the physiological counterplayers of kinases
and are responsible for their deactivation, may play an
additional role in cardiac protection by facilitating higher
activity levels and/or prolonged phosphorylation states of
individual kinases.
Speci®c aspects
Adenosine is considered to be one of the most relevant
triggers of early and late preconditioning.87 Adenosine is
released from cells in the ischaemic zone by upregulation of
Fig 1 Signalling for cardiac preconditioning. The signalling components depicted illustrate current knowledge regarding the mechanisms of early (left
of dashed line) and delayed (right of dashed line) cardiac preconditioning. DYm=inner mitochondrial membrane potential; AlRed=aldose reductase;
Bcl-2=anti-apoptotic protein; Ca=sarcolemmal voltage-dependent Ca2+ channels; DAG=diacylglycerol; COX-2=cyclooxygenase type 2;
eNOS=endothelial NO synthase; G-proteins=heterotrimeric G-proteins; HSP27 and HSP70=heat shock proteins; iNOS=inducible NO synthase;
IP3=inositol triphosphate; IP3R=inositol triphosphate receptor; K=sarcolemmal and mitochondrial KATP channels; MnSOD=manganese superoxide
dismutase; NF-kB=nuclear factor-kB; NO=nitric oxide; PIP2=phosphatidylinositol bisphosphate; PKC=protein kinase C; PLC/PLD=phospholipases C
and D; ROS=reactive oxygen species; RYR=ryanodine Ca2+-release channel; SERCA2=Ca2+ pump of the SR; SR=sarcoplasmic reticulum.
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ectosolic or membrane-associated 5¢-nucleotidase (respon-
sible for adenosine phosphate ester dephosphorylation)44
and activates the respective receptors on cardiomyocytes in
an autacoid manner. A3 receptor-initiated protection seems
to last longer than A1 receptor-initiated protection, which
may be explained by the differential coupling of the A1
receptor to phospholipase C and the A3 receptor to
phospholipase D.12 Consistent with the pivotal role of
adenosine, Haedrick and colleagues28 reported marked
cardioprotection against ischaemia in murine hearts over-
expressing A1 receptors. Adenosine may be less important
as an effective preconditioning trigger in the rat heart
model,54 where a-adrenergic receptors (mainly a1B) play a
major role.36 In contrast, in rabbit and canine hearts a-
adrenergic receptor agonists abolish preconditioning. These
observations support the concept that multiple receptor
systems of varying importance can contribute to cardiopro-
tection in different animal models (Fig. 1).
ROS are important intracellular signalling molecules and
are increased during sublethal oxidative stress (precondi-
tioning stimulus). They play a pivotal role in triggering
early and delayed cardioprotection and are probably derived
from mitochondria.13 ROS activate phospholipase C and
PKC, which, in turn, amplify the preconditioning stimulus.
Murry and colleagues70 ®rst demonstrated that administra-
tion of radical scavengers blocks the bene®cial effects of
early ischaemic preconditioning. Evidence for an essential
role of ROS in the establishment of late preconditioning was
reported by Sun and colleagues.100 Thus, generation of ROS
during the initiation of preconditioning represents an
essential trigger for early and delayed cardioprotection.
NO is able to induce a cardioprotective effect against
myocardial stunning and infarction. Recent studies provided
direct evidence of enhanced biosynthesis of NO in the
myocardium subjected to brief episodes of ischaemia and
reperfusion, probably via increased (endogenous constitu-
tive) NOS activity.7 Although most studies indicate that
endogenous NO is not necessary for ischaemia-induced
early preconditioning, exogenous or pharmacologically
increased endogenous NO production elicits an early
preconditioning effect (i.e. NO is suf®cient but not neces-
sary for early preconditioning).7 Conversely, NO has an
obligatory role in late preconditioning.27
Fig 2 Cytoprotective mechanisms of cardiac preconditioning. The
sarcolemmal and mitochondrial KATP channels, the sarcolemmal voltage-
dependent Ca2+ channel and the mitochondrial permeability transition
pore (PTP) are shown. The differently marked bars in the mitochondrial
intermembrane space represent the supramolecular complex (SMC)
containing the proton pump, ATP synthase, the adenine nucleotide
transporter and mitochondrial creatine kinase. Boldness and direction of
arrows represent relative intensity and direction of ion ¯ux. (A) Under
normal conditions, the cytosolic Ca2+ concentration is governed mainly
by duration of the action potential (AP) and the resting membrane
potential. The Ca2+ uniporter is dependent on the mitochondrial inner
membrane potential. (B) During ischaemia±reperfusion injury, the
increased cytosolic Ca2+ concentration induces high metabolic activity
with accumulation of inorganic phosphate and reactive oxygen species.
This is accompanied by swelling of the intermembrane space, with
subsequent shrinkage of the mitochondrial matrix and disruption of the
SMC. This impairs energy production and nucleotide transport, resulting
in cellular ATP depletion. The PTP opens and induces dissipation of the
inner membrane potential, leading to cell death. (C) Ischaemic and
pharmacological preconditioning are thought to exert cardioprotection,
®rst by activation of the sarcolemmal KATP channel, which reduces the
intracellular Ca2+ by stabilization of the resting membrane potential
below ±80 mV and shortening of the AP. Secondly, activation of the
mitochondrial KATP channel leads to an increase in the mitochondrial
matrix volume and concomitantly reduces the intermembrane space,
which leads to reassembly of the SMC, closure or maintenance of the
closed state of the PTP, and restoration of mitochondrial energy
production.99 109
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Late or delayed preconditioning (delayed acquisition
of tolerance to ischaemia)
In contrast to early preconditioning, late preconditioning
requires NO formation and increased synthesis of protective
proteins (for detailed review see reference 7). Again, PKC
and multiple kinases are involved in the signalling cascade,
leading to activation of several transcription factors, such as
nuclear factor-kB (NF-kB), which leads to the sustained
expression of a number of proteins thought to be responsible
for the delayed protection phase (right part of Fig. 1).
Disruption of the inducible NOS (iNOS) gene completely
abrogates the delayed infarct-sparing effect, which points to
the obligatory role of inducible NOS in the cardioprotection
afforded by delayed preconditioning.27 Because of the
dominant role of NO, late preconditioning is viewed as a
state of enhanced NO synthesis, NO acting as a trigger
(produced by constitutive NOS) initially and subsequently
as an effector (produced by inducible NOS). The most likely
cardioprotective effects of NO in late preconditioning are:
(i) inhibition of Ca2+ in¯ux; (ii) antagonism of b-adrenergic
stimulation; (iii) reduced contractility and myocardial
oxygen consumption; (iv) opening of KATP channels; (v)
antioxidant actions; and (vi) activation of COX-2 with the
synthesis of prostanoids. Other enzymes associated with
delayed protection are aldose reductase, which catalyses
sorbitol to glucose and detoxi®es ROS-derived lipid
aldehydes, manganese superoxide dismutase (MnSOD),
and the anti-apoptotic protein Bcl-2. Biosynthesis of heat
shock proteins (Hsp27, Hsp70) is not increased, but this
family of protective proteins is subject to post-translational
modi®cation.17 Recent ®ndings also indicate that activation
of mitochondrial KATP channels plays a role in delayed
protection, as 5-hydroxydecanoate (a speci®c mitochondrial
KATP channel blocker), administered immediately before
sustained ischaemia, can inhibit protection elicited 24 h
after the initial preconditioning stimulus.5
Pharmacology of sarcolemmal and mitochondrial
KATP channels, the putative end-effectors of
preconditioning
Cardiomyocytes have two distinct types of KATP channels,
one located in the surface membrane and another in the
inner mitochondrial membrane (Figs 1 and 2) (for review
see reference 26). Preconditioning can be pharmacologi-
cally mimicked by KATP channel openers and abolished by
KATP channel inhibitors (Table 1). Sarcolemmal KATP
channels are colocalized (i.e. physically bound)15 with the
creatine phosphate±creatine kinase system and provide a
direct link between the metabolic state and cellular excit-
ability. Mitochondrial KATP channels regulate mitochon-
drial volume state, mitochondrial membrane potential,
formation of ROS and energy production. The molecular
structure of mitochondrial KATP channels is largely
unknown. In contrast, sarcolemmal KATP channels are
composed of hetero-octamers of four pore-forming subunits
(four Kir6.1 or Kir6.2 subunits form an inward-rectifying
K+ channel with a conductance of 80 pS) and four
sulfonylurea receptors (SUR1, SUR2A or SUR2B). The
most common expression pattern of sarcolemmal KATP
channels is Kir6.2/SUR1 in the pancreas, Kir6.1/SUR2B
and Kir6.2/SUR2B in vascular smooth muscle, and Kir6.2/
SUR2A in the heart. Kir6.2/SUR2A is responsible for the
early depolarization in ischaemic heart tissue, which
represents the basis for the clinically observed `injury
current' of ischaemia (molecular basis of ischaemic ECG
ST-segment changes).53
Recent studies demonstrate that mitochondrial KATP
channels closely resemble Kir6.1/SUR1 sarcolemmal
KATP channels, at least in their pharmacological pro®le.
Diazoxide, a highly speci®c mitochondrial channel activator
(2000-fold more speci®c for the mitochondrial channel),
opens mitochondrial channel activity, 5-hydroxydecanoate
inhibits it and HMR-1098 does not affect it.57 This does not
mean that mitochondrial channels are identical with Kir6.1/
SUR1. Kir6.1 is not colocalized with mitochondria, and
dominant-negative Kir6.1 or Kir6.2 constructs did not affect
mitochondrial ¯avoprotein oxidation,94 a direct and highly
speci®c indicator of mitochondrial KATP channel activity.
Patch-clamp studies in isolated mitoplasts (planar lipid
bilayers of mitochondrial membranes) also demonstrated a
much smaller conductance for mitochondrial KATP channels
(~10±56 pS).38 In the heart, the sarcolemmal KATP channels
(and most probably also the mitochondrial KATP channels)
are not active under physiological conditions, where ATP at
a concentration of ~1 mM allosterically inhibits the Kir6.x
subunits, thus binding to and stabilizing the closed state of
the channel (Table 1). A low cellular ATP content under
ischaemic conditions effectively activates the KATP chan-
nels. Conversely, SURx subunits confer high-af®nity block-
ade by sulfonylurea agents and stimulation by KATP channel
openers and MgADP. Mitochondrial KATP channels are
regulated differently and are inhibited by ATP and ADP, but
activated by GTP and GDP.25 Also, while palmitoyl- and
Table 1 Pharmacology of mitochondrial and sarcolemmal KATP channels.
ATP=adenosine triphosphate; CoA=coenzyme A; GDP=guanosine
diphosphate; GTP=guanosine triphosphate; UDP=uridine diphosphate
Selectivity Agonists Antagonists
Sarcolemmal Long-chain CoA esters HMR-1098
P-1075
ADP
Mitochondrial GTP ADP
GDP Long-chain-CoA esters
UDP 5-Hydroxydecanoate
Superoxide anions
Diazoxide
Nicorandil
BMS-191095
Non-selective Cromakalim ATP
Bimakalim Glibenclamide
Aprikalim Glyburide
Diethylaminoethylbenzoate
Pinacidil
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oleyl-CoA facilitate opening of the sarcolemmal KATP
channel, they have inhibitory effects on the mitochondrial
KATP channel
82 (Table 1). Recent research has uncovered
the dominant role of the mitochondrial KATP channels in
mediating the preconditioned state (for review see reference
74). The sarcolemmal KATP channel, which was thought
initially to be the main end-effector of preconditioning, did
not explain why reduction in infarct size was observed even
in the case of unchanged action potential duration. Also,
defetilide, a K+ channel blocker (class III antiarrhythmic)
with no effects on KATP channels, abolished shortening of
the action potential but failed to remove the protection
provided by ischaemic preconditioning. However, recent
research in transgenic mice lacking the sarcolemmal KATP
channels (Kir6.2±/±) indicates that sarcolemmal KATP
channels may be important, at least in the murine heart,
which has a high baseline heart rate (5±10 Hz).101
Interestingly, Toyoda and colleagues108 suggested a differ-
ential role of sarcolemmal and mitochondrial KATP channels
in preconditioning, whereby infarct size reduction is
mediated largely by mitochondrial KATP channels, but
functional recovery (in which heart rate plays a pivotal role)
is mediated by sarcolemmal KATP channels. Mitochondrial
KATP channels also play an important role in the prevention
of cardiomyocyte apoptosis1 and in delayed preconditioning
protection.7 Considerable cross-talk was recently reported
between sarcolemmal and mitochondrial KATP channels.
92
Accordingly, increased ATP consumption through un-
coupled mitochondria leads to activation of sarcolemmal
KATP channels. Thus, although a preponderance of experi-
mental work favours the mitochondrial KATP channels as
the main end-effector of preconditioning, the role of
sarcolemmal KATP channels cannot be dismissed totally.
How might the KATP channels modulate infarct size?
The cellular consequences of the opening of the KATP
channels are depicted in Figure 2A±C.
Sarcolemmal KATP channels
Although the intracellular Ca2+ transients for contraction
and relaxation are governed mainly by the Ca2+ pump
(SERCA2) and the ryanodine Ca2+-release channel (RYR)
in the sarcoplasmic reticulum, a signi®cant amount of the
cytosolic Ca2+ is recruited from the extracellular space,
mainly via the Na+/Ca2+ exchanger and the voltage-gated L-
type Ca2+ channels (Fig. 1). Membrane hyperpolarization,
by the opening of sarcolemmal KATP channels, as in
cardioplegia, may shorten action potential duration (Fig. 2C).
As a consequence, less Ca2+ enters the myocytes from
outside and attenuates Ca2+ overload.
Mitochondrial KATP channels
Three main concepts, which do not exclude, but rather
complement, each other, are currently under investigation
(Fig. 2). According to MarbaÂn and his group, opening of the
mitochondrial KATP channel leads to depolarization of the
inner mitochondrial membrane.68 Uncoupling of mitochon-
dria and increased formation of ROS have been reported
previously.22 Although this change is modest, it has a
signi®cant effect on mitochondrial Ca2+ load because of the
non-linear dependence of Ca2+ ¯ux on the membrane
potential. It is hypothesized that depolarization of the inner
mitochondrial membrane (by 12% at a diazoxide concen-
tration of 10 mmol litre±1, corresponding to a change from
±200 to ±176 mV) attenuates mitochondrial Ca2+ accumu-
lation by lowering the driving force for Ca2+ uptake. The
decreased mitochondrial Ca2+ overload during ischaemia114
may prevent opening of the mitochondrial permeability
transition pores and guarantee optimal conditions for ATP
production.35 Conversely, mitochondrial matrix contraction
(~30%) and intermembrane space expansion is a direct
consequence of anoxic blockade of electron transport during
ischaemia (Fig. 2B). While mitochondrial K+ in¯ux ceases
(a compensatory consequence of the H+ pumping from the
matrix into the intermembrane space), mitochondrial K+
ef¯ux (K+/H+ antiporter) continues until a new equilibrium
Table 2 Volatile anaesthetics, opioids, ethanol-based anaesthetics, and urethane with mostly enhancing effects on mitochondrial and sarcolemmal KATP
channels. ¬®=no effect; ­=increased effect; ¯=decreased effect; *increased open probability of sarcolemmal KATP channels for a given ATP concentration
in response to iso¯urane, but iso¯urane itself inhibits the sarcolemmal KATP channel or has no effect on the channel; **induces stunning, which could result
from inhibitory effects on sarcolemmal and/or mitochondrial KATP channels
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Anaesthetic drug Mitochondrial
KATP channel activity
References Sarcolemmal KATP
channel activity
References
Iso¯urane ­ 45, 120 ­ / ¯ / ¬®* 24, 30, 50, 90
Sevo¯urane ­ 45, 120 ?
Des¯urane ­ 31, 104 ­ 104
Halothane ? ¯ 50, 90
En¯urane ? ?
Nitrous oxide** ? ?
Morphine ­ 55 ?
Fentanyl ­ 119 ?
Sufentanil ? ?
Remifentanil ? ?
Trichloroethanol (chloral hydrate, a-chloralose) ­ 119 ?
Ethanol ­ 77 ­ 77
Urethane ­ 119 ?
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at a lower matrix volume is reached. This leads to
dissociation of the mitochondrial creatine kinase octameric
complex from the outer and inner membranes.51 Garlid and
colleagues now propose that opening of the mitochondrial
KATP channel decreases the ischaemia-induced swelling of
the mitochondrial interspace, which would preserve func-
tional coupling between adenosine nucleotide translocase
and mitochondrial creatine kinase (preservation of structure/
function).47 51 This, in turn, secures the transport of newly
synthesized ATP from the site of production by ATP
synthase on the inner mitochondrial membrane to the
cytosol. Thus, both mechanisms contribute to an uninter-
rupted supply of high-energy phosphate substrates from the
mitochondria to the sites of energy consumption. A third
possibility for the means by which mitochondrial KATP
channels may elicit protection is based on the observation of
the increased formation of ROS (generation of a pro-oxidant
environment probably derived from the cytochrome b-c1
segment of complex III of the respiratory chain).22 Pain and
colleagues78 demonstrated that diazoxide is protective even
if it is only present before (rather than during) the sustained
ischaemia, which implies that mitochondrial KATP channel
opening would serve as a trigger of preconditioning, but
would not mediate cardioprotection per se (effector).
According to this concept, ROS (or the intracellular redox
state) would stimulate the activation of multiple transcrip-
tional factors (NF-kB, activator protein-1, hypoxia-
inducible factor, protein kinases, protein phosphatases and
various ion channels (Ca2+/K+/Na+ channels, Na+/Ca2+ or
Na+/H+ exchanger)), ultimately leading to cardioprotection.
Other mechanisms involved in cardiac preconditioning
In whole-organ preparations and in vivo experiments,
preconditioning protection is also attributable to the
protective effects on the endothelium of the coronary
vasculature,52 the inhibition of platelet aggregation34 and
leucocyte adhesion.43 Thus, the bene®ts of preconditioning
clearly extend beyond the cardiomyocyte.
Anaesthetic-induced preconditioning
Preconditioning can be pharmacologically elicited by
anaesthetics. Volatile anaesthetics, opioids and a small
group of anaesthetics primarily used in animal experiments
were found to induce or enhance preconditioning in cardiac
tissue. Table 2 summarizes the effects of these anaesthetics
on mitochondrial and sarcolemmal KATP channels. Current
knowledge about anaesthetic-induced preconditioning from
in vitro systems and animal experiments will now be
discussed. Evidence for anaesthetic-induced precondition-
ing in humans will be presented in Part II of this review.118
Fig 3 Signalling pathways involved in volatile anaesthetic-induced preconditioning. The signalling cascades that are listed derive from the results of
recently published studies using the indicated blockers and activators.24 31 45 50 67 90 104 119 120 Multiple signalling cascades prime the sarcolemmal
and mitochondrial KATP channels, allowing prompt opening at the initiation of ischaemia. Arrows indicate positive activity and lines with blunted ends
(=) indicate inhibition. Ad=adenosine; CHE=chelerythrine (protein kinase C inhibitor); DAG=diacylglycerol; DIAZO=diazoxide (speci®c opener of
the mitochondrial KATP channel); DPCPX=8-cyclopentyl-1,3-dipropylxanthine (speci®c adenosine 1 receptor blocker); Gas/Gai/Gaq/Gbg=different
G-protein species; 5HD=5-hydroxydecanoate (selective mitochondrial KATP channel blocker); HMR-1098=speci®c blocker of the sarcolemmal KATP
channel; L-NIL=L-N6-(1-iminoethyl)lysine; IP3=inositol triphosphate; L-NAME=NG-nitro-L-arginine methyl ester (L-NIL and L-NAME are nitric
oxide synthase inhibitors); MnTBAP=Mn(III)tetrakis(4-benzoic acid)porphyrine chloride; MPG=N-(2-mercaptopropionyl)glycine (MnTBAP and MPG
are free radical scavengers); NO=nitric oxide; NOS=nitric oxide synthase; PKC=protein kinase C; PLC=phospholipase C; PTIO=2-(4-carboxyphenyl)-
4,4¢,5,5¢-tetramethylimidazole-1-oxyl-3-oxide (nitric oxide scavenger); PTX=pertussis toxin (Gai-protein inhibitor); R=receptor; ROS=reactive oxygen
species; SNAP=S-nitroso-N-acetyl-DL-penicillamine (nitric oxide donor); SPT=8-sulfophenyl theophylline (non-speci®c adenosine receptor blocker).
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Volatile anaesthetics
Most studies have evaluated the cardiac preconditioning
effects of iso¯urane, en¯urane and halothane,64 115 and
more recently those of sevo¯urane2 106 and des¯urane.104
The favourable oxygen supply/demand ratio elicited by
volatile anaesthetics is not required for preconditioning
because volatile anaesthetic-induced protection also occurs
under cardioplegic arrest.58 Many characteristics of pre-
conditioning by volatile anaesthetics are similar to those of
ischaemic preconditioning. These involve activation of A1
adenosine receptors, PKC and KATP channels. Of note,
ischaemic preconditioning and anaesthetic preconditioning
(2 3 2 min with sevo¯urane at 3.5 vol/vol % interspersed
with 5 min of reperfusion) similarly reduce Ca2+ loading,
augment post-ischaemic contractile responsiveness to Ca2+
and decrease infarct size.2 Whether volatile anaesthetics
also elicit late preconditioning is not yet known, but
preliminary data indicate that volatile anaesthetics may
exert additive effects in combination with ischaemic
preconditioning.106 Iso¯urane and sevo¯urane induce an
acute `memory phase', which is more pronounced with
iso¯urane (>30 min) than sevo¯urane (<30 min).106 For
both anaesthetics, dose-dependent protection was demon-
strated in a cellular model of isolated adult rat ventricular
myocytes.120 Dose-dependent protection by iso¯urane was
also reported in an in vivo dog model of regional ischaemia,
in which as little as 0.25 MAC iso¯urane (0.3 vol/vol %,
which is close to 1 MACawake in humans) signi®cantly
reduced infarct size.40 Interestingly, iso¯urane protection
depended on collateral blood ¯ow at low MAC values
but was independent of collateral ¯ow at higher MAC
values. The maximum preconditioning protection was
reached at an iso¯urane concentration of approximately
1.5±2 vol/vol %.40 120
Key signalling components involved in preconditioning
elicited by volatile anaesthetics were unravelled recently by
means of speci®c blockers for signalling steps (Fig. 3).
Using an in vivo rabbit model with regional ischaemia
combined with a Langendorff model, Cope and colleagues14
showed that 8-sulfophenyl theophylline, a non-speci®c
adenosine receptor blocker, inhibited the preconditioning
effect of halothane. The effect was also inhibited by
chelerythrine, a highly speci®c PKC blocker. Similarly,
high doses of bisindolylmaleimide, a PKC inhibitor,
blocked iso¯urane-enhanced recovery of canine stunned
myocardium.107 Iso¯urane and halothane are known to
affect PKC activity. PKC-induced coronary vasoconstric-
tion is inhibited by halothane, but enhanced by iso¯urane.79
Another study indicated that neither iso¯urane nor
halothane inhibited PKC-induced alterations in coronary
vascular tone.76 As in Cope's study,14 Cason and col-
leagues9 demonstrated in an in vivo rabbit model with
regional ischaemia that 8-sulfophenyl theophylline could
inhibit iso¯urane-mediated preconditioning. In a dog model
of regional ischaemia, Kersten and colleagues41 reported
that the effects of iso¯urane on post-ischaemic recovery
were partially inhibited by 8-cyclophenyl-1,3-dipropyl-
xanthine, an adenosine 1-speci®c receptor blocker. In this
study, iso¯urane-induced protection was associated with
decreases in endogenous adenosine release, which is the
opposite of what is observed in ischaemic preconditioning.
A1 receptors were also found to mediate protection in
iso¯urane- but not halothane-treated human atrial trabecular
strips31 and myocytes.90 Toller and colleagues105 reported
the important role of Gi-proteins in establishing the
iso¯urane-induced preconditioned state by showing com-
plete blockade of preconditioning in response to pertussis
toxin before treatment in an in vivo dog model of regional
ischaemia. The signi®cance of all these signalling
components could be con®rmed at the cellular level using
adult rat ventricular myocytes.120
In many studies, non-speci®c blockers of the sarco-
lemmal and mitochondrial KATP channel identi®ed these
channels as important in volatile anaesthetic-induced
preconditioning. The question of whether the sarcolemmal
KATP channel or the mitochondrial KATP channel is more
important in mediating volatile anaesthetic-induced pre-
conditioning has been addressed in several experimental
studies.33 104 120 It is important to note that considerable
cross-talk is now documented between sarcolemmal and
mitochondrial KATP channels,
92 and that the importance of
the individual KATP channels may vary among experimental
approaches and animal models. Zaugg and colleagues120
showed that protection by iso¯urane and sevo¯urane is
selectively mediated by activation of mitochondrial KATP
channels in a cellular model of non-beating cardiomyocytes.
Also, Hanouz and colleagues31 demonstrated that des¯ur-
ane-induced preconditioning is inhibited by 5-hydroxyde-
canoate (a selective mitochondrial KATP channel inhibitor)
but not HMR-1098 (a selective sarcolemmal KATP channel
inhibitor) in human right atria. Conversely, Toller and
colleagues104 reported that both KATP channels may be
involved in des¯urane-mediated preconditioning in an
in vivo dog model of regional ischaemia. In accordance
with the results of Zaugg and colleagues,120 mitochondrial
KATP channels were found to mediate iso¯urane protection
selectively in an in vivo rabbit model.85 Similarly, Shimizu
and colleagues95 reported the inhibition of iso¯urane
preconditioning by 5-hydroxydecanoate (a speci®c blocker
of the mitochondrial KATP channel) in isolated perfused rat
hearts, and Nakae and colleagues71 reported that nicorandil
(a speci®c activator of mitochondrial KATP channels) did
not have infarct-size limiting effects in halothane anaes-
thetized rabbits. Conversely, Piriou and colleagues85 dem-
onstrated additive bene®cial effects when coadministering
nicorandil (a speci®c activator of mitochondrial KATP
channels) with iso¯urane. This discrepancy among reports
showing that either mitochondrial or sarcolemmal KATP
channels are more important may be due to the different
experimental approaches, species differences (rat vs dog), or
fundamental differences between anaesthetics.
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Results from patch-clamp experiments demonstrated
either an increased open probability of the sarcolemmal
KATP channel for a given ATP concentration in response to
iso¯urane but inhibitory effects on overall channel activity
(excised patch con®guration),30 or no effect on sarcolemmal
KATP channel activity at all (whole-cell and excised patch
con®guration).24 90 In contrast to iso¯urane, halothane
inhibits the sarcolemmal KATP channel in human
90 and
guinea-pig myocytes.50 Iso¯urane facilitates cardiac sarco-
lemmal KATP channels preactivated by the non-speci®c
KATP channel opener pinacidil,
50 the PKC activator phorbol
12,13-dibutyrate and the metabolic inhibitor 2,4-dinitro-
phenol,24 indicating a priming effect of these agents on this
channel. Two recent studies addressed the effect of volatile
anaesthetics on mitochondrial KATP channels. In both
studies, myocyte-inherent ¯avoprotein-induced ¯uores-
cence (auto¯uorescence) was used to measure mitochon-
drial KATP channel activity. MarbaÂn and his group
93 showed
that the redox state of these endogenous ¯uorophores
directly re¯ected mitochondrial KATP channel activity, and
that the opening of this channel was closely associated with
signi®cant protection against ischaemia. Kohro and col-
leagues45 demonstrated in guinea-pig myocytes that mito-
chondrial KATP channel activity was increased by 10%
when exposed to iso¯urane 0.7 mM or sevo¯urane 1 mM.
Administration of propofol or pentobarbital abrogated this
effect. However, the concentrations used in these experi-
ments were high (2±3 vol/vol % for iso¯urane and 4±5 vol/
vol % for sevo¯urane, corresponding to more than 2 MAC
iso¯urane or sevo¯urane at 37°C), and the effect on the
mitochondrial KATP channel was small compared with other
preconditioning drugs. These observations may re¯ect toxic
effects of volatile anaesthetics on oxidative phosphorylation
rather than pharmacologically relevant effects on mitochon-
drial KATP channels. In the study by Zaugg and col-
leagues,120 iso¯urane and sevo¯urane did not elicit
increased channel activity per se at lower concentrations,
but enhanced diazoxide-induced ¯avoprotein oxidation.
These results support the concept of channel priming by
volatile anaesthetics, which was described recently by Sato
and colleagues.93 They proposed a resting, primed and open
state of the mitochondrial KATP channel on the basis of the
observation that adenosine did not affect basal mitochon-
drial KATP channels but signi®cantly enhanced opening by
diazoxide, a highly selective opener of mitochondrial KATP
channels. This concept of channel priming (including the
sarcolemmal and the mitochondrial KATP channel) also
appears to extend to iso¯urane- and sevo¯urane-induced
preconditioning. The primed channel state allows easy and
rapid opening at the initiation of ischaemia. In their studies,
Zaugg and colleagues120 also presented evidence that
volatile anaesthetics mediate their protection by selectively
enhancing mitochondrial KATP channels through the trig-
gering of multiple PKC-coupled signalling pathways,
namely NO and adenosine/Gi signalling pathways. An
overwhelming body of evidence now demonstrates that
biosynthesis of NO plays a pivotal role in decreasing
ischaemic damage in heart tissue.7 It is not surprising,
therefore, that NO and cGMP may be major players in
volatile anaesthetic-induced protection. NO/cGMP signal-
ling and basal NOS activity were reported to play a
fundamental role in pacing associated-preconditioning in
the isolated heart.102 It may well be that volatile anaesthetics
differentially modulate the activity of the various isoen-
zymes of NOS (nNOS, eNOS, iNOS), which are ubiquitous
but heterogeneously distributed in myocytes. The observa-
tion that iso¯urane-induced preconditioning (2% vol/vol) in
a-chloralose-anaesthetized rabbits is inhibited by free
radical scavengers supports the concept that generation of
radicals, either by means of altered NO synthesis or by
enhanced formation of ROS/NO (possibly by opening
mitochondrial KATP channels), is important.
67 Recently,
des¯urane-induced preconditioning was shown to be
inhibited by phentolamine (a-adrenergic blockade) and
propranolol (b-adrenergic blockade), which is in accord-
ance with the notion that des¯urane releases a signi®cant
amount of catecholamines in cardiac tissue.32 It may be that
low and high concentrations of volatile anaesthetics activate
distinct signalling pathways, resulting in sequential acti-
vation of the two KATP channel subtypes. Taken together,
these results show that the preconditioning effects of
volatile anaesthetics are triggered by multiple signalling
cascades and mediated mainly by mitochondrial KATP
channels, but sarcolemmal KATP channels may also con-
tribute to the protection elicited by volatile anaesthetics.
The cardioprotective effects of volatile anaesthetics can
be enhanced by cariporide, a Na+±H+ exchange inhibitor.62
One additional interesting mechanism by which volatile
anaesthetics could elicit their protection was described by
Piriou and colleagues.84 In this study, the use of gadolinium
to block mechano-gated channels, which are activated by
iso¯urane,80 abolished iso¯urane-induced preconditioning.
Pre-ischaemic administration of volatile anaesthetics is also
known to decrease the incidence of post-ischaemic
ventricular arrhythmias, particularly in small animals,8
whereas in larger animals (dogs, pigs) this is more
controversial.29 Volatile anaesthetics also vasodilate coron-
ary arteries by activation of endothelium KATP channels,
16
increase endothelial-dependent and endothelial-independ-
ent post-ischaemic basal coronary ¯ow, and promote
endothelial NO release.73 Preserved NO generation also
prevents leucocyte adhesion and migration (in¯ammatory
response), and blocks expression of adhesion molecules.
One study demonstrated improved vascular endothelial
protection if volatile anaesthetics were administered during
low-¯ow perfusion for 1 day at 3°C.97 This indicates
signi®cant microvascular protection by volatile anaes-
thetics. Most recently, pretreatment with iso¯urane before
cytokine exposure increased the survival of human
endothelial and smooth muscle cells, an affect that was
abrogated by PKC or KATP channel inhibition.
20
Importantly, protective effects by endothelial precondition-
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ing appear to be bene®cial for up to 1 month and may apply
to a wide variety of tissues, including all vital organs.59
Opioids
The existence of k- and d-opioid receptors, but not m-
receptors, has been reported in rat atrial and ventricular
tissue.48 In addition, cardiomyocytes constantly release
opioids into the circulation, particularly during stressful
stimuli, and thereby serve as an endocrine organ.65
Activation of opioid receptors results in a potent cardio-
protective effect similar to classical and delayed precondi-
tioning. Currently, it is thought that selective activation of
d1 opioid agonists exert this protection via interaction with
Gi-proteins and activation of PKC, tyrosine kinases (and
possibly other kinases, such as MAPK), and ultimately
KATP channels.
23 Some studies report opioid-induced
preconditioning effects, which are independent of direct
receptor stimulation and are mediated solely by free radical
formation.81 As with ischaemic preconditioning, activation
of d-opioid receptors also protects the heart from arrhyth-
mias. Although the d-opioid receptor is the most prominent
receptor subtype in opioid-induced cardioprotection,4 some
role for k-receptors cannot be dismissed, particularly in
protection against ventricular ®brillation.113 Opioid recep-
tor-mediated protection is stereoselective, as protection can
be abolished only by the (±)-active stereoisomer of
naloxone.11 Using a cellular model of simulated ischaemia
in chicken cardiomyocytes, Liang and colleagues55 showed
that morphine 1 mM elicited the same protection as
preconditioning with 5 min of ischaemia. In this study,
morphine effects were abolished by 5-hydroxydecanoate (a
speci®c mitochondrial KATP channel blocker), which again
emphasizes the dominant role of mitochondrial KATP
channels in preconditioning. Interaction of d-opioid agonists
with KATP channels was ®rst shown in neuronal tissue, in
which analgesia produced by d-opioid receptor activation
could be antagonized by glibenclamide.117 Recently, Zaugg
and colleagues119 demonstrated that fentanyl enhanced
diazoxide-induced mitochondrial KATP channel activity,
which was inhibited by the PKC inhibitor chelerythrine.
Again, this observation is consistent with a priming effect of
fentanyl on mitochondrial KATP channels. Conversely, in an
isolated perfused rat heart model, sufentanil did not improve
post-ischaemic recovery, but produced an increase in left
ventricular end-diastolic pressure during reperfusion.63 The
clinical relevance of opioid-induced cardioprotection is not
yet clear. This topic will be discussed in Part II of this
review.118
Ethanol-based anaesthetics (chloral hydrate, a-
chloralose) and urethane
Zaugg and colleagues119 recently showed that 2,2,2-
trichloroethanol, a halogenated analogue of ethanol and
the active metabolite of chloral hydrate and a-chloralose,
enhanced mitochondrial KATP channel activity via acti-
vation of PKC. Though not commonly used clinically, these
two anaesthetics are still used extensively in experimental
investigations. The cardioprotective role of ethanol in
ischaemia±reperfusion has been reported previously. In a
cellular model of simulated ischaemia, ethanol mimicked
preconditioning by activation of PKC.10 Its preconditioning
effects could also be demonstrated in dogs fed chronically
with ethanol.77 Zaugg and colleagues119 further reported
cardiac preconditioning effects by urethane, mediated by
mitochondrial KATP channels in a PKC-dependent manner.
As many anaesthetics clearly affect KATP channels (Table 2)
and thereby modify preconditioning, investigations into the
precise mechanisms of preconditioning need to consider the
effects of background anaesthesia. Experimental results
need to be interpreted in the light of these ®ndings.
Conclusions
This review summarizes current knowledge about the key
cellular events involved in ischaemic and anaesthetic
preconditioning. Although many characteristics of anaes-
thetic preconditioning are similar to ischaemic precondi-
tioning, there may be fundamental differences with respect
to signal intensity and the potential to concomitantly harm
cardiac tissue. Understanding of the multiple signalling
steps and the ultimate cytoprotective mechanisms is an
important prerequisite for both the design of future basic
research studies and the evaluation of the clinical effects of
ischaemic and anaesthetic-induced preconditioning.
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Addendum
During the review process for this article, important studies
on basic principles underlying cardiac preconditioning and,
in particular, anaesthetic preconditioning were published.
The most salient ®ndings of these are brie¯y summarized
here.
Controversy surrounding the main end-effector in
early preconditioning: mitochondrial vs
sarcolemmal KATP channelsÐa never-ending story
A recent study by Suzuki and colleagues121 demonstrated
loss of diazoxide-mediated post-ischaemic functional
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improvement in mice lacking the sarcolemmal KATP
channels. This study has the following important implica-
tions. First, although it cannot be totally excluded that
knockout of sarcolemmal KATP channels may arti®cially
increase ischaemic damage and thereby cancel the effect of
ischaemic preconditioning, the results of this study reinforce
the importance of sarcolemmal KATP channels in the
development of cardioprotection in the murine model.
Secondly, the ®ndings of this study provide evidence that
diazoxide may have signi®cant effects on sarcolemmal
KATP channels, questioning its mitochondrial selectivity in
some species (mouse vs rat). Finally, results obtained from
mouse hearts should not be extrapolated directly to larger
animal models. In another recent study,122 a mixed agonist/
antagonist (MCC-134) with opposing effects on sarcolem-
mal and mitochondrial KATP channels was identi®ed. MCC-
134 inhibited diazoxide-induced ¯avoprotein oxidation and
at the same time opened sarcolemmal KATP channels in
mouse and rabbit cardiomyocytes. In the in vivo mouse
model, MCC-134 abolished the effect of ischaemic
preconditioning against infarction, suggesting that, even in
mice, mitochondrial KATP channels are the key players in
cardioprotection. In accordance with this concept, several
recent publications suggest that mitochondrial KATP chan-
nels may be more important than sarcolemmal KATP
channels in anaesthetic-induced preconditioning.123±125
The metabolic concept of cardiac preconditioning
This concept provides an alternative explanation for the
preconditioning process without assuming the existence of
mitochondrial KATP channels, which have not yet been
cloned. According to this model, agents such as pinacidil,
nicorandil and volatile anaesthetics would target enzymes of
the respiratory chain directly. A recent report by Hanley and
colleagues126 showed that diazoxide and 5-hydroxydecano-
ate have KATP channel-independent targets in the heart,
diazoxide inhibiting succinate dehydrogenase and 5-hy-
droxydecanoate serving as a substrate for acyl-CoA
synthetase (fatty acid oxidation). These observations raise
the possibility that inhibition of key enzymes in the
tricarboxylic acid cycle and the respiratory chain may
initially lead to a reduction in ROS formation and
mitochondrial ATPase activity and subsequently (at the
time of washout of the agent) induce a burst of free radicals.
The sequence of these events would mimic the precondi-
tioning process and ultimately induce protection.127 128 In
this scenario, 5-hydroxydecanoate would abrogate precon-
ditioning by increasing the electron ¯ow to the respiratory
chain, thereby circumventing the inhibitory effects of
diazoxide on succinate dehydrogenase. In fact, 5-hydro-
xydecanoate is metabolized by acyl-CoA-dehydrogenase
and may thus increase the supply of electrons to the
respiratory chain.
Lack of delayed protection in volatile anaesthetic-
induced preconditioning?
Kehl and colleagues129 showed that iso¯urane (1 MAC,
corresponding to 1.28 vol%) administered for 6 h in dogs
does not produce a second window of protection (SWOP)
against coronary occlusion 24 h later. However, other
temporal relationships for the occurrence of a SWOP were
not tested. Also, this study failed to show effective delayed
preconditioning by ischaemia as an important positive
control in the experimental setting used.
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